PBAC Recommendation versus PBS Approval

Independent Review of PBAC

Neural versus neurofuzzy systems for credit approval

Registration and Reimbursement of New Cancer Medicines in Australia.

I read with interest the article by Macaulay et al. [1] in a recent issue of Value in Health Regional Issues for Asia on the registration and reimbursement of certain medicines for patients with cancer in Australia. This topic is of considerable public interest in Australia given the current Senate inquiry on timely access to new medicines for patients with cancer on the Pharmaceutical Benefits...

Affordable access to innovative cancer medicines - don't forget the prices.

In Australia, HTAs for medicines are carried out in two phases. First, a pharmaceutical company makes a submission to the Therapeutic Goods Administration, which assesses a medicine’s efficacy and safety. If the medicine is approved, an application can be made to the Pharmaceutical Benefits Advisory Committee (PBAC) to have the medicine subsidised by the Pharmaceutical Benefits Scheme (PBS). Th...

Is Approval Voting Optimal Given Approval Votes?

Some crowdsourcing platforms ask workers to express their opinions by approving a set of k good alternatives. It seems that the only reasonable way to aggregate these k-approval votes is the approval voting rule, which simply counts the number of times each alternative was approved. We challenge this assertion by proposing a probabilistic framework of noisy voting, and asking whether approval v...